Allegretti Lab: Andrew Allegretti, MD, MSc

Overview

Hepatorenal syndrome is complicated disease that results from a number of factors related to kidney and liver health. As a clinical and translational researcher, I work to understand current treatments for patients with this disease through two main pathways. First, we perform large epidemiologic analyses to optimize current therapies (such as vasoconstrictive medications, dialysis, or transjugular intrahepatic portosystemic shunt [TIPS] placement). Second, we are exploring new mechanisms and treatments for hepatorenal syndrome by examining regulators of vascular inflammation and endothelial cell dysfunction (such as Angiopoietin/Tie2 signaling). We have a growing biorepository of blood and urine samples of patients with hepatorenal syndrome that we use to improve testing and treatment of this population. We have ongoing collaborations between research centers in Nephrology and Hepatology at MGH, Beth Israel Deaconess Medical Center, and the Liver Unit at the University of Barcelona.

References

1. Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. American Journal of Kidney Diseases. 2016; 68: 381-91.
2. Allegretti AS, Vela Parada X, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI. Prognosis of patients with cirrhosis and acute kidney injury who initiate renal replacement therapy. Clinical Journal of the American Society of Nephrology. 2018; 13(1):16-25.
3. Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi, M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT. Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology. 2019; 69(2):729-741.

Additional Information

• Full Bibliography
• Lab Website